$CHPT is leading the Prism MarketView EV index today after the company narrowed its net loss and posted higher-than-expected revenue in its fiscal third quarter
| PRISM Stock Indexes | Current Value | % Change (Daily) | % Change (Inception) | Most Active | Top % Gainers | Top % Losers |
|---|---|---|---|---|---|---|
| AI Datacenter and Infrastructure | $467.30 | 0.8% | 367.3% | APLD 15,563 | TSSI 7.676% | SLNH -2.208% |
| AdTech and Media | $166.10 | -1.4% | 66.1% | FUBO 9,945 | IHRT 6.061% | BBLR -11.765% |
| Biotech | $133.60 | -1.8% | 33.6% | TSHA 4,052 | CAPR 14.23% | PALI -15.049% |
| Cannabis | $79.80 | 0.9% | -20.2% | TLRY 25,758 | AYRWF 12.871% | HITI -5.46% |
| Consumer Products | $104.60 | 0.1% | 4.6% | PTON 17,209 | BBW 22.6% | OTLY -5.421% |
| EV | $72.30 | 1.7% | -27.7% | LCID 51,984 | EZFL 26% | LTHM -8.532% |
| Global Health | $261.20 | -2.7% | 161.2% | ESPR 4,252 | ALGS 8.495% | NKGN -10.523% |
| Healthcare | $81.80 | -0.5% | -18.2% | BMRA 840 | CCLD 12.857% | OWLT -8.163% |
| NextGen Tech & AI | $215.00 | 0.2% | 115.0% | SOUN 29,555 | SOUN 31.33% | FTFT -10.854% |
| New Energy | $87.30 | -0.6% | -12.7% | DNN 20,843 | UROY 12.393% | NOVA -5.733% |
| MedDevices | $120.20 | -2.1% | 20.2% | HUMA 3,050 | MYO 11.215% | PAVM -12.829% |
| Mental Health | $64.50 | -3.6% | -35.5% | BNOX 9,628 | RVPH 14.4% | SEEL -31.494% |
| Oil & Gas | $86.70 | -0.7% | -13.3% | KOS 7,778 | ALVOF 3.175% | ICD -9.877% |
| Pharmaceuticals | $166.80 | -2.1% | 66.8% | TNXP 37,537 | CADL 10.61% | BDRX -19.7% |
| Psychedelics | $251.60 | -4.5% | 151.6% | MIRA 1,485 | ENVB 3.835% | RLMD -28.571% |
| Weight Loss | $223.50 | -4.1% | 123.5% | HIMS 15,491 | SRRK 5.255% | RSLS -11.786% |
| Women’s Health | $144.60 | 0.4% | 44.6% | ITRM 2,627 | ITRM 18.828% | PDSB -6.977% |
The holiday season has kicked off and is now in full swing as consumers pulled out their pocketbooks to make their Black Friday and Cyber Monday purchases. It comes as no surprise that Black Friday had more success from online sales than in-store. According to Mastercard SpendingPulse, this Black Friday online sales surged 14.6% year-over-year (y/y), significantly outpacing in-store sales, which rose a modest 0.7%. Cyber Mondayreinforced online retail strength with Adobe Analytics reporting Americans spent $13.3Bn, up 7.3% from last year. Besides the convenience, the online sales uptick is attributed to steeper discounts and a persistent push from retailers that included mass emailing, push notifications, chat bot assistance and ‘buy now, pay later’ services which hit $991M in spending. (more…)
In light of Alzheimer’s Awareness Month, Klotho Neurosciences COO, Peter Moriarty, discusses how the Klotho gene in its secreted form may hold the key to treating multiple neurodegenerative diseases.
November is Alzheimer’s Awareness Month which focuses on increasing understanding of Alzheimer’s and the impact it has on the 6.2 million Americans suffering from the disease. Alzheimer’s disease is a progressive, age-related neurodegenerative disease affecting memory, cognition, and behavior. It is the most common cause of dementia, accounting for 60-80% of cases. Historically, Alzheimer’s treatments focused on managing symptoms without addressing the disease’s underlying biology. However, a new generation of therapies is targeting key mechanisms, such as protein accumulation, inflammation, and disrupted neuronal communication.
Recent groundbreaking research and emerging therapies have been aimed at enhancing human health and longevity. In particular, researchers have examined the secreted form of the Klotho gene, or s-KL and its powerful role in aging, which may hold the key to healthier aging and the treatment of devastating diseases like Alzheimer’s, ALS, and Parkinson’s.
PRISM MarketView spoke with Klotho Neurosciences (Nasdaq: KLTO) Chief Operating Officer, Peter Moriarty, who shared insights on what scientists know about the secreted form of Klotho, the exciting research surrounding it, and what the future might hold for this potential anti-aging therapy.
$CHPT is leading the Prism MarketView EV index today after the company narrowed its net loss and posted higher-than-expected revenue in its fiscal third quarter
$CAPR is the biggest laggard of the Prism MarketView Biotech index and is trading at the lower end of its range over the past couple of months which looks to be an important support level in the near term.
$ESPR is leading the Prism MarketView Public Health Index after the company said it has filed new submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein cholesterol and cardiovascular risk.
